SterisFRA:2TG +11.53%90 EBITDA Margin % is 27.89% as of Mar. 2026, which is 13% above its 10-year median of 24.59. GuruFocus rates FRA:2TG with a GF Score™ of 90/100 and a GF Value™ of €238.39 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Steris ranks better than 87.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Steris's EBITDA for the
three
months ended in Mar. 2026 was €383 Mil. Steris's Revenue for the
three
months ended in Mar. 2026 was €1,374 Mil. Therefore, Steris's EBITDA margin for the quarter that ended in Mar. 2026 was 27.89%.
Steris (FRA:2TG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Steris EBITDA Margin % Related Terms
Steris EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Steris's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2TG vs ZBH, GEHC, DXCM: EBITDA Margin % Comparison
For the Medical Devices subindustry, Steris's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Steris's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steris (FRA:2TG) has a EBITDA Margin % of 27.89% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Steris and its competitors. This is 13% above median its historical median of 24.59. Over the past decade, Steris' EBITDA Margin % has ranged from 15.97 to 29.63. According to the industry distribution chart, Steris ranks #104 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 12.7%.
Is Steris' EBITDA Margin % too high?
Steris' current EBITDA Margin % of 27.89% is 13% above median its 10-year median of 24.59. Over the past 10 years, this metric has ranged from a low of 15.97 to a high of 29.63. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Steris' value of 27.89% is 273.1% above this industry median. Based on the distribution chart, Steris ranks #104 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Steris has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' EBITDA Margin % compare to ZBH and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #104 out of 816 companies for EBITDA Margin %. This places Steris in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Steris' value of 27.89% is 273.1% above this benchmark. Historically, Steris' own EBITDA Margin % has ranged from 15.97 to 29.63 over the past decade. While the company's 10-year median is 24.59 vs. the industry median of 7.48, Steris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current EBITDA Margin % of 27.89% is 273.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Steris and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current EBITDA Margin % is 27.89%, which is 13% above median its own 10-year median of 24.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (FRA:2TG) is currently considered Modestly Undervalued. The stock's GF Value™ is €238.39, compared to a current price of €183.80 — trading 22.9% below its estimated fair value. The current EBITDA Margin % is 27.89%, which is 13% above median its 10-year median of 24.59 and 273.1% above the Medical Devices & Instruments industry median of 7.48. Steris' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Steris (FRA:2TG), the current EBITDA Margin % is 27.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (FRA:2TG) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of €183.80 is trading 22.9% below its estimated GF Value™ of €238.39.
GuruFocus considers Steris to be Modestly Undervalued.
Key valuation signals for FRA:2TG:
EBITDA Margin %: 27.89% (13% above median its 10-year median of 24.59)
GF Value™: €238.39 vs. price of €183.80 (22.9% below fair value)
Industry Position: 273.1% above the Medical Devices & Instruments median (#104 of 816)
No single metric tells the full story. See the FRA:2TG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
90GF Score
Get the complete analysis for FRA:2TG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2TG has been successfully added to your 
